An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Male or female participant aged 18 to 65 years (inclusive), at the time of the informed consent is signed. * Participants must have AD as defined by the American Academy of Dermatology Consensus Criteria (2014) for 1 year or longer before signing of informed consent. * The EASI score ≥16 at Screening and Check-in (Day -1). * vIGA-AD score ≥3 (on the 0 to 4 vIGA-AD scale) at Screening and Check-in (Day -1). * AD involvement of ≥10% body surface area at Screening and Check-in (Day -1). * Participants must have documented history within 6 months prior to Screening and Check-in (Day -1), of either inadequate response (including inadequate efficacy or medical inadvisability) of topical treatments. * Body weight within 40 to 150 kg at Screening and Day 1 and body mass index (BMI) \<40 kg/m2 (inclusive). * Capable of giving signed informed consent. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Known history of significant immunosuppression or suspected current significant immunosuppression, including history of invasive opportunistic, or helminthic infections. * Any malignancies or history of malignancies prior to baseline (except for non-melanoma skin cancer that has been excised and cured for more than 5 years prior to baseline). * Any concomitant illness that would, in the Investigator's opinion, inh…